| |JUNE 20268TOP STORIESBIG RELIEF FOR PATIENTS AS HP INVESTS RS 150 CRORE IN DIAGNOSTICSFTC APPROVAL PAVES WAY FOR AUROBINDO PHARMA'S LANNETT DEALSUN PHARMA'S LATEST ACQUISITION TARGETS FAST-GROWING WELLNESS SECTORGUJARAT'S SICKLE CELL MISSION SHOWS THE POWER OF EARLY DETECTIONARE GENERIC CANCER DRUGS DRIVING INDIA PHARMA GROWTH?Himachal Pradesh invests Rs 150 crore in diagnostics as the state government moves to strengthen healthcare infrastructure across the state. Chief Minister Sukhvinder Singh Sukhu announced a major funding package to modernize laboratories in all government medical colleges, aiming to improve diagnostic services and patient care.The announcement was made during the foundation stone-laying ceremony of a new critical care block at Dr. Radhakrishnan Government Medical College, Hamirpur. The decision comes as the state pushes ahead with healthcare reforms and infrastructure upgrades. With HP investing Rs 150 crore in diagnostics, medical colleges are expected to receive advanced laboratory equipment and upgraded facilities that can support faster and more accurate disease detection. POAurobindo Pharma has moved a step closer to completing its USD 250 million acquisition of Lannett Company after receiving approval from the US Federal Trade Sun Pharma's latest acquisition marks another strategic step in its efforts to strengthen its presence beyond traditional pharmaceuticals. The company has announced the acquisition of Innovcare Lifesciences for Rs 271.2 crore in an all-cash deal, expanding its footprint in the fast-growing nutraceutical and wellness market. With Sun Pharma's latest acquisition, the drugmaker aims to enhance its consumer healthcare portfolio and tap into rising demand for preventive healthcare, nutrition, and wellness products across India. The acquisition will see Sun Pharmaceutical Industries Ltd acquire a 100 percent stake in Innovcare Lifesciences. The transaction is expected to be completed on or before July 31, 2025, subject to customary closing conditions. POCommission (FTC). The regulatory clearance marks a major milestone for the transaction and removes one of the biggest hurdles in the deal process.With the FTC approval in place, Aurobindo Pharma is now expected to complete the acquisition shortly, subject to customary closing conditions and the completion of agreed divestitures. The acquisition is expected to strengthen Aurobindo Pharma's presence in the United States, expand its product portfolio, and enhance its manufacturing capabilities in one of the world's largest pharmaceutical markets. POIndia's oncology landscape is undergoing a significant transformation as generic cancer drugs improve treatment accessibility while driving innovation and market expansion. With rising cancer incidence and increasing demand for cost-effective therapies, generics are emerging as a critical pillar in bridging affordability gaps and expanding patient reach across the country.The shift is not only enhancing treatment availability but also strengthening India's position as a key player in the global oncology generics market, where innovation is increasingly aligned with accessibility. One of the most defining contributions of generic oncology drugs in India has been their role in improving affordability. POGujarat's Sickle Cell Mission has emerged as one of India's most successful
< Page 7 | Page 9 >